Solid Biosciences (SLDB) Interest Coverage Ratio (2023 - 2025)
Solid Biosciences (SLDB) posted Interest Coverage Ratio of 10.55 for Q1 2026, up 6.36% sequentially from 11.27 in Q4 2025, and up 96.31% YoY from 5.38 in Q1 2025.
Analysis
Solid Biosciences (SLDB) Interest Coverage Ratio (2023 - 2025) Analysis & Trends
Solid Biosciences has reported Interest Coverage Ratio for 10 years, with the latest figure at 10.55 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 96.31% year-over-year to 10.55 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 36.17 (up 96.46% YoY) and the FY2025 annual result came in at 0.94, up 5.2% from the prior year.
- Interest Coverage Ratio rose to 10.55 in Q1 2026 per SLDB's latest filing, from 11.27 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.21 in Q4 2022 and troughed at 497.49 in Q1 2022.
- A 5-year average of 176.93 and a median of 208.05 in 2022 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2023 and 2026: Interest Coverage Ratio sank 2431.42% in 2023, then jumped 96.31% in 2026.
- Over 5 years, Interest Coverage Ratio stood at 0.21 in 2022, then tumbled by 2431.42% to 5.35 in 2023, then plunged by 86.49% to 9.98 in 2024, then declined by 12.95% to 11.27 in 2025, then climbed by 6.36% to 10.55 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 10.55, 11.27, and 29.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Solid Biosciences | 1.48 Bn | 1.48 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -9,880.60 |
| Sep 30, 2025 | 143.03 |
| Jun 30, 2025 | -694.88 |
| Mar 31, 2025 | -589.00 |
| Dec 31, 2024 | -531.95 |
| Sep 30, 2024 | -429.05 |
| Jun 30, 2024 | -315.77 |
| Mar 31, 2024 | -282.76 |
| Dec 31, 2023 | -220.45 |
| Sep 30, 2023 | -218.06 |
| Jun 30, 2023 | -241.83 |
| Mar 31, 2023 | -264.71 |